Brought to you by 
Cardiovascular Diagnostics to develop test for Lilly drug
08 May 2015
Executive Summary
Cardiovascular Diagnostics (point-of-care (POC) hemostasis tests) will develop a POC test using its Thrombolytic Assessment System (TAS) for an Eli Lilly therapeutic anticoagulant under development to treat sepsis.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Hematology, Coagulation
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cardiovascular Diagnostics to develop test for Lilly drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice